Northwestern Mutual Wealth Management Co. Reduces Stake in ICU Medical, Inc. (NASDAQ:ICUI)

Northwestern Mutual Wealth Management Co. reduced its position in ICU Medical, Inc. (NASDAQ:ICUI) by 44.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,827 shares of the medical instruments supplier’s stock after selling 120,172 shares during the period. Northwestern Mutual Wealth Management Co. owned about 0.62% of ICU Medical worth $18,030,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Motco acquired a new position in ICU Medical in the first quarter valued at $29,000. Innealta Capital LLC bought a new stake in ICU Medical in the second quarter valued at about $32,000. GAMMA Investing LLC increased its holdings in ICU Medical by 75.1% in the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 133 shares during the last quarter. EntryPoint Capital LLC grew its holdings in shares of ICU Medical by 731.5% during the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 395 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of ICU Medical by 46.4% during the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 173 shares during the period. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,096,771.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, VP Daniel Woolson sold 2,502 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $17,096,771.78. The disclosure for this sale can be found here. Insiders sold a total of 28,552 shares of company stock worth $4,537,802 over the last ninety days. 6.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ICUI has been the subject of a number of recent research reports. KeyCorp increased their price objective on ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Thursday, August 8th. Finally, Raymond James raised their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $149.00.

ICU Medical Stock Up 4.4 %

Shares of NASDAQ ICUI opened at $182.22 on Tuesday. The firm’s 50-day moving average is $155.95 and its 200-day moving average is $124.76. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. ICU Medical, Inc. has a 1 year low of $78.28 and a 1 year high of $188.53. The firm has a market capitalization of $4.44 billion, a PE ratio of -74.38 and a beta of 0.65.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The firm had revenue of $596.50 million during the quarter, compared to analysts’ expectations of $556.64 million. During the same period in the previous year, the firm earned $1.58 earnings per share. The company’s revenue was up 8.6% on a year-over-year basis. Equities analysts expect that ICU Medical, Inc. will post 3.76 EPS for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.